Author:
Hassani Nouriyeh Mandana,Afshar Mogaddam Mohammad Reza,Nemati Mahboob,Farajzadeh Mir Ali,Abbasalizadeh Aysa,Shahedi Hojghan Ali
Funder
Tabriz University of Medical Sciences
Reference43 articles.
1. Sunitinib: from rational design to clinical efficacy;Chow;J. Clin. Oncol.,2007
2. Regorafenib and reactive metabolite of sunitinib activate inflammasomes: implications for multi tyrosine kinase inhibitor-induced immune related adverse events;Kato;Int. J. Pharm. Sci.,2022
3. A simple and fast LC-MS/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma;Jolibois;J. Chromatogr. B,2019
4. Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy?;Méjean;Eur. Urol.,2021
5. Analytical methods for determination of different members of FDA approved tyrosine kinase inhibitors like dasatinib, lapatinib, imatinib, sorafenib, nintedanib, sunitinib and pazopanib: a review;Sankar;J. Pharm. Sci. Res.,2021